SG10201809427SA - Insulin receptor partial agonists - Google Patents

Insulin receptor partial agonists

Info

Publication number
SG10201809427SA
SG10201809427SA SG10201809427SA SG10201809427SA SG10201809427SA SG 10201809427S A SG10201809427S A SG 10201809427SA SG 10201809427S A SG10201809427S A SG 10201809427SA SG 10201809427S A SG10201809427S A SG 10201809427SA SG 10201809427S A SG10201809427S A SG 10201809427SA
Authority
SG
Singapore
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
SG10201809427SA
Other languages
English (en)
Inventor
Songnian Lin
Lin Yan
Pei Huo
Dmitri Pissarnitski
Danqing Feng
Ravi Nargund
Yuping Zhu
Ahmet Kekec
Christina Madsen-Duggan
Zhi-Cai Shi
Zhicai Wu
Yingjun Mu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10201809427SA publication Critical patent/SG10201809427SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG10201809427SA 2014-11-21 2015-11-19 Insulin receptor partial agonists SG10201809427SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
SG10201809427SA true SG10201809427SA (en) 2018-11-29

Family

ID=54838417

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809428UA SG10201809428UA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809428UA SG10201809428UA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Country Status (27)

Country Link
US (4) US20170355743A1 (ko)
EP (4) EP3666792A3 (ko)
JP (5) JP6484337B2 (ko)
KR (2) KR102049647B1 (ko)
CN (2) CN112494656B (ko)
AR (1) AR102712A1 (ko)
AU (3) AU2015349890B2 (ko)
BR (2) BR122024000903A2 (ko)
CA (2) CA2966765C (ko)
CL (3) CL2017001288A1 (ko)
CO (1) CO2017004976A2 (ko)
CR (1) CR20170208A (ko)
DO (1) DOP2017000124A (ko)
EA (1) EA036714B1 (ko)
ES (1) ES2946247T3 (ko)
GT (1) GT201700104A (ko)
IL (1) IL252257A0 (ko)
MX (3) MX2017006651A (ko)
NI (1) NI201700060A (ko)
PE (1) PE20170957A1 (ko)
PH (1) PH12017500935A1 (ko)
SG (4) SG10201809457YA (ko)
SV (1) SV2017005445A (ko)
TN (1) TN2017000178A1 (ko)
TW (1) TW201625673A (ko)
WO (1) WO2016081670A2 (ko)
ZA (1) ZA201703238B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170682A1 (es) 2014-08-04 2017-06-15 Nuevolution As Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
US20170355743A1 (en) 2014-11-21 2017-12-14 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3463429A4 (en) * 2016-05-24 2020-07-22 Merck Sharp & Dohme Corp. PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES
WO2017205309A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
CN109891237B (zh) * 2016-10-24 2022-08-23 诺和诺德股份有限公司 胰岛素制剂的生物测定法
EP3668892A1 (en) 2017-08-17 2020-06-24 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519605A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2022046747A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
KR20230079068A (ko) * 2020-09-03 2023-06-05 다인 세라퓨틱스, 인크. 단백질-올리고뉴클레오티드 복합체의 제조 방법
EP4210729A2 (en) * 2020-09-09 2023-07-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
AU4672699A (en) * 1998-06-08 1999-12-30 Theravance, Inc. Novel sodium channel drugs and uses
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
DK2226316T3 (en) 2002-05-30 2016-04-11 Scripps Research Inst Copper catalyzed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
US20090197800A1 (en) 2004-10-27 2009-08-06 Novo Nordisk A/S Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
ES2545533T3 (es) 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AU2009240636A1 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
DK2349324T3 (en) * 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
EP2376521B1 (en) 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
US9908925B2 (en) * 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
CA2904198A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
MX366852B (es) * 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
EP3068443B1 (en) * 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
US20170355743A1 (en) 2014-11-21 2017-12-14 Merck Sharp & Dohme Corp. Insulin receptor partial agonists

Also Published As

Publication number Publication date
PE20170957A1 (es) 2017-07-13
US20190092833A1 (en) 2019-03-28
SG10201809457YA (en) 2018-11-29
CR20170208A (es) 2017-07-17
US10800827B2 (en) 2020-10-13
NI201700060A (es) 2017-07-18
CL2019001143A1 (es) 2019-07-19
TW201625673A (zh) 2016-07-16
KR102101136B1 (ko) 2020-04-14
EP3660040A2 (en) 2020-06-03
KR20190069622A (ko) 2019-06-19
EP3666792A3 (en) 2020-07-29
JP6931033B2 (ja) 2021-09-01
ZA201703238B (en) 2018-05-30
JP6703068B2 (ja) 2020-06-03
IL252257A0 (en) 2017-07-31
EP3666792A2 (en) 2020-06-17
AU2018211208B2 (en) 2020-09-10
CN112494656A (zh) 2021-03-16
AU2018211207B2 (en) 2020-04-09
AU2015349890B2 (en) 2018-08-30
TN2017000178A1 (en) 2018-10-19
US20170107268A1 (en) 2017-04-20
EP3221343B1 (en) 2020-09-16
MX2020014121A (es) 2021-03-25
AU2018211208A1 (en) 2018-08-16
US10017556B2 (en) 2018-07-10
JP6943825B2 (ja) 2021-10-06
US20170355743A1 (en) 2017-12-14
EP3660041A1 (en) 2020-06-03
CL2017001288A1 (es) 2017-12-15
JP2019011357A (ja) 2019-01-24
US10183981B2 (en) 2019-01-22
EA201791117A1 (ru) 2017-11-30
US20180291078A1 (en) 2018-10-11
EA036714B1 (ru) 2020-12-10
CA2966765A1 (en) 2016-05-26
CA3014641C (en) 2020-08-18
SG10201809428UA (en) 2018-11-29
JP2018501203A (ja) 2018-01-18
WO2016081670A2 (en) 2016-05-26
KR102049647B1 (ko) 2019-11-29
BR112017010481A8 (pt) 2023-04-11
JP2019014735A (ja) 2019-01-31
ES2946247T3 (es) 2023-07-14
AU2015349890A1 (en) 2017-06-01
CN112494656B (zh) 2024-01-30
JP6484337B2 (ja) 2019-03-13
BR122024000898A2 (pt) 2024-02-27
MX2020014120A (es) 2021-03-25
KR20170084300A (ko) 2017-07-19
AU2018211207A1 (en) 2018-08-16
GT201700104A (es) 2018-11-27
CN108064173B (zh) 2021-05-18
CA3014641A1 (en) 2016-05-26
CN108064173A (zh) 2018-05-22
JP2019014734A (ja) 2019-01-31
WO2016081670A3 (en) 2016-08-04
EP3660040A3 (en) 2020-07-29
BR122024000903A2 (pt) 2024-02-27
JP2020097572A (ja) 2020-06-25
EP3660041B1 (en) 2023-04-19
CO2017004976A2 (es) 2017-10-10
SG11201704064TA (en) 2017-06-29
PH12017500935A1 (en) 2017-11-27
BR112017010481A2 (pt) 2018-04-03
AR102712A1 (es) 2017-03-22
DOP2017000124A (es) 2017-08-15
CL2019001144A1 (es) 2019-07-19
EP3221343A2 (en) 2017-09-27
MX2017006651A (es) 2017-08-21
SV2017005445A (es) 2018-04-04
CA2966765C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
SG10201809457YA (en) Insulin receptor partial agonists
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2020012893A (es) Formulaciones de proteinas.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019011297A (es) Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MY167350A (en) Fat-and-oil composition and chocolate
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
NZ744340A (en) Anti-jagged1 antibodies and methods of use
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния